Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows used in operating activities:
Net loss	$ (13,465)	$ (10,060)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,740	2,798
Operating lease right-of-use asset	55	20
Depreciation	32	50
Amortization of premium on bonds	283
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,971)	(77)
Other Assets	65
Accounts payable	938	1,934
Accrued expenses	(545)	(1,811)
Operating lease liabilities	(52)
Net cash used in operating activities	(11,920)	(7,146)
Cash flows (used in)/provided by investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.		3,719
Purchase of marketable debt securities, available-for-sale	(97,959)
Purchase of property and equipment	(290)	(247)
Net cash (used in)/provided by investing activities	(98,249)	3,472
Cash flows (used in)/provided by financing activities:
Proceeds from - ArTara Private Placement, net of offering costs		1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs		12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs		25,319
Repurchase of shares in connection with settlement of RSUs	(228)
Repayments under short-term debt		(370)
Net cash (used in)/provided by financing activities	(228)	39,229
Net (decrease)/increase in cash and cash equivalents and restricted cash	(110,397)	35,555
Cash and cash equivalents and restricted cash - beginning of year	169,393	564
Cash and cash equivalents and restricted cash - end of period	58,996	36,119
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	58,201	36,069
Restricted cash	50	50
Restricted cash, long-term	745
Cash and cash equivalents and restricted cash	58,996	36,119
Cash paid for:
Interest		8
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses		122
Purchase of insurance agreement with notes payable		1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.		$ 34,533